§ Federal grant opportunity · RFA-DK-27-140
Rigor and Reproducibility for Biomarkers in Type 1 Diabetes Clinical Research
National Institutes of Health is accepting applications for Rigor and Reproducibility for Biomarkers in Type 1 Diabetes Clinical Research. The deadline is Rolling / not published and the published award range is Award amount not published.
Key facts
- Funder
- National Institutes of Health
- Application deadline
- Rolling / not published
- Award range
- Award amount not published
- Eligibility
- for profit organizations other than small businesses, public and state institutions of higher education, small businesses, state governments, other native american tribal organizations, special district governments, public and indian housing authorities, nonprofits non higher education with 501c3, private institutions of higher education, independent school districts, nonprofits non higher education without 501c3, other, federally recognized native american tribal governments, county governments
- Geography
- United States
- Focus areas
- Health
- Opportunity number
- RFA-DK-27-140
Program overview
The main goal of this initiative is to establish a consortium with the overarching goal to advance the systematic identification, rigorous evaluation, validation, and assays harmonization of biomarkers that are critical to the prevention, diagnosis, and clinical management of Type 1 Diabetes (T1D). Despite significant advances in T1D research, there remains an urgent need for reliable and reproducible biomarkers that can capture the complexity of autoimmune processes, metabolic dysregulation, and individual patient variability. This initiative will leverage state-of-the-art methodologies in clinical chemistry, genomics, proteomics, metabolomics, immunophenotyping, and imaging, coupled with longitudinal patient cohorts and mining of Electronic Health Records (EHR). Within this consortium major efforts will be devoted to: 1) Harmonize established assays for biomarkers such as HbA1c and c-peptide, making sure that these assays are performed in a rigorous and reproducible manner in the clinical research community and in clinical practice. For this purpose, reference methods and materials will use a metrology approach and will be made available to the community; 2) Identify and validate other biomarkers that can be used for the prevention, diagnosis, and clinical management of T1D. It has been reported that the assays for several biomarkers routinely used in clinical research such as glucagon, amylin, chromogranin, insulin, pro-insulin and other pro-hormones are not reproducible across platforms or laboratories. For this purpose, this consortium will ensure that all assays for biomarkers routinely used in clinical research and for newly identified biomarkers are rigorously validated and assessed for reproducibility across several laboratories following a metrology approach.
How to apply
- Confirm your organization meets the eligibility criteria above.
- Read the full funding opportunity announcement from National Institutes of Health.
- Draft your narrative against the funder's stated priorities and review criteria.
- Submit before Rolling / not published, allowing time for registration and validation.
Related grant opportunities
- Restoring Joint Health and Function to Reduce Pain (RE-JOIN) 2.0
- Pediatric and Reproductive Environmental Health Scholars (PREHS) Program
- Illuminating AD/ADRD Genome to Enable Precision Genomic Medicine
- Controlled Clinical Trials on Long-Term Effects of Nutritional Interventions on the Progression of Risk Factors for Age-Related Chronic Conditions Over the Life Span and Their Age of Onset
- Understanding Cerebellar Contributions to Cognitive and Affective Functions in Aging and Alzheimer's Disease/Alzheimer's Disease-Related Dementias
Find every grant your organization qualifies for
Mavenly scores this opportunity against your mission, geography, and funding history — then drafts the proposal with you and tracks the deadline through submission and reporting.